Clinical Trial

A Study to Assess the Safety of ARGX-213 in Healthy Volunteers

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to assess the safety of ARGX-213 in healthy adults. Another aim is to measure the amount of ARGX-213 in the blood over time to learn how it moves through the body and acts in the body. The participants will remain in the study for approximately up to 21 weeks.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-05; most recent amendment 2026-04-22.
Status change: Recruiting → Completed 2026-04-22
Trial Details
NCT Number NCT06968338
Lead Sponsor argenx
Conditions Healthy Volunteers
Enrollment 88 participants
Start Date 2025-04-11
Primary Completion 2026-03-20 (estimated)
Study Completion 2026-03-20 (estimated)
Updated on ClinicalTrials.gov 2026-04-23